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ABSTRACT  
 
MALT lymphoma originates from a background of diverse chronic inflammatory disorders at various 
anatomic sites.  The genetics underlying its development, particularly in those associated with 
autoimmune disorders, is poorly characterised.  By whole exome sequencing of 21 cases of MALT 
lymphomas of the salivary gland and thyroid, we have identified recurrent somatic mutations in 2 G-
protein coupled receptors (GPR34 and CCR6) not previously reported in human malignancies, 3 
genes (PIK3CD, TET2, TNFRSF14) not previously implicated in MALT lymphoma, and a further 2 genes 
(TBL1XR1, NOTCH1) recently described in MALT lymphoma.   The majority of mutations in GPR34 
and CCR6 were nonsense and frameshift changes clustered in the C-terminal cytoplasmic tail, and 
would result in truncated proteins that lack the phosphorylation motif important for β-arrestin 
mediated receptor desensitization and internalisation.  Screening of these newly identified 
mutations, together with previously defined genetic changes, revealed distinct mutation profiles in 
MALT lymphoma of various sites, with those of salivary gland characterised by frequent TBL1XR1 and 
GPR34 mutations, thyroid by frequent TET2, TNFRSF14 and PIK3CD mutations, and ocular adnexa by 
frequent TNFAIP3 mutation.  Interestingly, in MALT lymphoma of the salivary gland, there was a 
significant positive association between TBL1XR1 mutation and GPR34 mutation/translocation 
(P=0.0002).  In those of ocular adnexa, TBL1XR1 mutation was mutually exclusive from TNFAIP3 
mutation (P=0.049), but significantly associated with IGHV3-23 usage (P=0.03) and PIK3CD mutation 
(P=0.009).  These findings unravel novel insights into the molecular mechanisms of MALT lymphoma 
and provide further evidence for potential oncogenic cooperation between receptor signalling and 
genetic changes.   
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INTRODUCTION 
 
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 
originates from acquired MALT at diverse anatomic sites.  Accordingly, its development is closely 
associated with distinct inflammatory disorders.  For example, MALT lymphomas of the stomach and 
ocular adnexa are associated with chronic infection by Helicobacter pylori and Chlamydia psittaci 
respectively, while those of the salivary gland and thyroid are associated with Sjögren syndrome and 
Hashimoto thyroiditis respectively.1  In addition to its diverse aetiology, MALT lymphomas of various 
sites also show distinct biased usage of IGHV.  For instance, up to a third of ocular adnexal MALT 
lymphomas have IGHV4-34 BCR that is most likely auto-reactive, binding to the carbohydrate I/i 
antigens, while more than 50% of salivary gland MALT lymphomas bear IGHV1-69 BCR with features 
of rheumatoid factors.2-9  These findings suggest that various chronic inflammatory disorders may 
generate immune responses, which preferentially expand B-cells with certain properties, such as 
autoreactive BCR, consequently leading to the development of MALT lymphoma.1,10       
 
There are a number of genetic changes described in MALT lymphomas, but many of these changes 
occur at considerable variable frequencies at different sites despite that they commonly affect the 
NF-B pathway.1    For example, t(11;18)(q21;q21)/API2-MALT1 and to a lesser extent 
t(1;14)(p22;q32)/BCL10-IGH are frequently seen in MALT lymphoma of the lung and stomach, but 
rarely or not in those of the salivary gland and thyroid.11-13  In contrast, TNFAIP3 mutation and/or 
deletion, which encodes a NF-B negative regulator, is frequent in MALT lymphoma of the ocular 
adnexa, but occurs at low frequencies in those of other sites.14-16  The reason for such dramatic 
differences in the genetics of MALT lymphomas of different sites is unclear, and it remains to be 
investigated whether the occurrence of these genetic changes is influenced by the distinct 
background disorders or vice versa.  
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The development of MALT lymphoma is the result of oncogenic cooperation between immunological 
drive and acquired genetic changes as neither the above genetic changes nor the immunological 
drive alone is sufficient for malignant transformation.  Nevertheless, the exact mechanisms of 
oncogenic cooperation in MALT lymphoma of various sites remain largely elusive.  In a recent study, 
we found a significant association between TNFAIP3 inactivation and biased IGHV4-34 usage in 
ocular adnexal MALT lymphoma, arguing for their cooperation in sustaining chronic BCR signalling, 
and thus NF-B activation.17  Interestingly, a very similar finding, namely a significant association 
between biased usage of IGHV1-2 and inactivating mutation of KLF2 (a negative regulator of NF-B), 
was previously reported in splenic marginal zone lymphoma.18   Taken together, such co-operation 
between antigenic stimulation and genetic abnormalities may represent a common feature in 
marginal zone B-cell lymphoma.  Nonetheless, this has not been fully investigated in marginal zone 
lymphoma of various sites, particularly in those of the salivary gland and thyroid, where very few 
genetic features have been identified.  In the present study, we first investigated the mutation 
profile of 21 MALT lymphomas of the salivary gland and thyroid by whole exome sequencing (WES), 
then validated the recurrent mutations in MALT lymphoma of various sites by targeted sequencing 
and finally investigated their association with IGHV usage.       
 
METHODS 
 
Patient samples and DNA exaction   
 
A total of 249 cases of MALT lymphoma were included in this study, originating from the ocular 
adnexa (n=115), salivary gland (n=58), stomach (n=36), thyroid (n=13), lung (n=13), and other sites 
(n=14).  179 of these cases were the subject of a previous study for somatic mutation in 17 genes..17  
Genomic DNA was extracted from tumour rich areas (>40%) of formalin fixed paraffin embedded 
(FFPE) lymphoma biopsies in 217 cases, and where possible from non-neoplastic cells by 
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microdissection using the QIAamp DNA micro kit (Qiagen, Netherlands).  Additionally, high molecular 
weight DNA was available in 32 cases of MALT lymphoma.   DNA quality was assessed by PCR 
amplification of variably sized genomic fragments, with those amenable to PCR of 300bp genomic 
fragment used for mutation analyses by targeted sequencing.19  Among the cases included in this 
study, clinical information such as site involvement and treatment details were available in 98 cases 
of ocular adnexal MALT lymphomas, and their correlation with genetic changes was examined.   
Local ethical guidelines for the use of archival tissues for research with the approval of the ethics 
committees of the involved institutions. 
 
Exome sequencing:  
 
A total of 21 MALT lymphomas (14 from salivary gland, 7 from thyroid) together with 1 matched 
non-neoplastic biopsy were investigated by whole exome sequencing (Table S1).  The initial 2 cases 
(1 thyroid and 1 salivary gland MALT lymphoma) were carried out on high molecular weight tumour 
DNA at the Eastern Sequence and Informatics Hub (EASIH).  Genomic libraries were prepared using 
the Illumina Truseq DNA sample preparation v2 kit (Illumina, California, USA), captured with the 
Nimblegen SeqCap EZ Exome v3 (Roche, Germany) and sequenced on an Illumina HiSeq platform.  
The remaining 19 cases (6 thyroid and 13 salivary gland MALT lymphoma) together with 1 matched 
non-neoplastic sample were performed on FFPE tissue DNA at the Wellcome Trust Sanger Institute.  
Genomic libraries were generated using the Illumina Paired End Sample Prep Kit, enriched using the 
Agilent SureSelect Human All Exon 50Mb kit (Agilent, California, USA), and sequenced on an Illumina 
HiSeq platform using a 75bp paired end protocol.  Sequencing reads were aligned to the hg19 
reference genome using BWA with default settings, with single nucleotide variants called by 
CaVEMan (Cancer Variants through Expectation Maximisation), and insertions and deletions by 
PINDEL.  Data were filtered against 300 unmatched normal controls available from the Cancer 
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Genome Project in addition to the 1000 genomes project and Ensembl variation databases to 
remove known single nucleotide polymorphisms (SNP).  
 
Somatic variant validation by Fluidigm Access Array PCR and Illumina MiSeq Sequencing 
 
Where indicated, the novel and shortlisted variants identified by WES were confirmed by PCR and 
Sanger Sequencing, and their somatic origin ascertained by PCR and Sanger sequencing analysis of 
DNA samples from microdissected non-neoplastic cells.   
 
Mutations in CCR6, FGFR3, FOXO1, GPR34, IKBKB, PIK3CD, NOTCH1, TBL1XR1, TET2 and TNFRSF14 
were then screened using the Fluidigm Access Array PCR and Illumina MiSeq protocol as previously 
described.19   Primer sequences and PCR conditions are shown in Table S2.  In addition, mutation in a 
further 17 genes including BCR signalling (CD79A, CD79B, CARD11), NF-B (TNFRSF11A, TNFAIP3, 
TRAF3), TLR signalling (MYD88), plasma cell differentiation (PRDM1), histone modifiers (CREBBP, 
EP300, EZH2, MLL2, MEF2B, KDM2B), antigen presentation (B2M, CD58), and apoptosis (TP53) were 
similarly screened in the cases (n=70) that were not investigated previously.17  Briefly, DNA samples 
were sequenced in duplicate and analysed using an in-house variant calling protocol optimised 
against a large panel of known mutations.19   Variants that appeared in both replicates at 10% AAF 
(alternative allele frequency) were further validated by inspection of their bam files, and then 
considered as true genetic changes.19  Where possible, variants were confirmed as somatic by PCR 
and Sanger sequencing of non-neoplastic DNA or assumed to be somatic if previously reported as 
somatic in the COSMIC database or other samples in the cohort.   
 
Fluorescent In Situ Hybridization (FISH) analysis 
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This was performed on FFPE tissue sections with Vysis LSI IGH Dual Colour Break Apart Probe (Abbott 
Molecular, Illinois, USA) and an in house GPR34 Dual Colour Break Apart probe as previously 
described.16,20 To generate the in house GPR34 break-apart probe, BAC clones RP11-643E21 and 
RP11-524P6 centromeric to GPR34, and RP11-360E17 and CTD-3202J9 telemeric to GPR34 were 
amplified using the Templiphi kit (GE Healthcare, Illinois,USA)  and then labelled with 
SpectrumOrange and SpectrumGreen respectively using nick translation with random priming 
(Abbott Molecular, Illinois, USA).16,20 
 
Sequencing analysis of the rearranged immunoglobulin heavy chain genes  
The sequence of clonally rearranged immunoglobulin heavy chain genes  was available in 94 cases 
from a previous study.17   Additional PCR and sequencing of the rearranged immunoglobulin heavy 
chain genes were performed for the cases investigated by whole exome sequencing using the 
BIOMED-2 VH FR1-JH or FR2-JH primers as described previuosly.17 Sequences were analysed using 
IMGT/V-Quest software (www.imgt.org/IMGT_vquest/vquest), and successfully annotated in a total 
of 101 cases (Table S3).   
 
Statistical analyses:  Fishers exact test was used to test for associations between categorical 
variables.   
 
RESULTS 
 
Novel mutations in MALT lymphomas identified by WES 
 
WES was successful in a total of 21 MALT lymphomas (14 from salivary gland, 7 from thyroid) 
together with 1 matched non-neoplastic DNA (Table S4).  After filtering known SNPs, synonymous 
changes and benign variants by Polyphen2, 72 variants were seen in the case with matched germline 
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DNA, while an average of 111 variants (range 46-264/case) were observed in the remaining cases 
without matched germline DNA (Figure S1).  Based on their frequencies, potential functional impact, 
involvement in cancer and lymphocyte biology and hits against relevant GO terms, novel variants in 
10 genes were selected for validation and their somatic origin was confirmed by Sanger sequencing 
of corresponding non-neoplastic DNA (Table S5).  These shortlisted genes included 2 G protein-
coupled receptors (GPR34, CCR6) not yet reported as a mutation target in human malignancies, 6 
(FGFR3, FOXO1, IKBKB, PIK3CD, TET2, TNFRSF14) not yet implicated in MALT lymphoma, and 2 
(TBL1XR1, NOTCH1) recently described in MALT lymphoma (Table S4, Figure S2).21  All of these 
mutations identified by WES were potentially pathogenic (please see section below).  To further 
investigate their mutation frequency and characteristics in MALT lymphoma, we screened a large 
cohort from various anatomic sites for mutations by Fluidigm Access Array PCR and Illumina MiSeq 
sequencing.    
 
Variable involvement of newly identified mutations in MALT lymphoma of different sites 
 
A total of 249 cases of MALT lymphoma from the ocular adnexa (n=115), salivary gland (n=58), 
stomach (n=36), thyroid (n=13), lung (n=13), and other sites (n=14) were investigated for somatic 
mutations in 27 genes with the 10 genes mentioned above investigated exclusively by the present 
study, and 17 genes studied by previous (n=149) and present (n=70) studies respectively (Table S6 
&7).17  Recurrent genetic changes are shown in Figure 1 (Figure S3).  Interestingly, the findings 
showed remarkable variations in their involvement among MALT lymphoma of different sites.   
 
GPR34 mutation was almost exclusively found in MALT lymphoma of salivary gland (9/56=16%), with 
exception of a single case from ocular adnexa (Figure 1).  The majority of GPR34 mutations were 
nonsense changes (6) and frameshift indel (1) that were clustered in the C-terminal regulatory 
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regions, resulting in truncated proteins (Figure 2).  The remaining 3 mutations were missense 
changes, namely R84H, D151A and Y327N.    
 
GPR34 is a G-protein coupled receptor (GPCR) and is deregulated by t(X:14)(p11.4;q32) in MALT 
lymphoma of salivary gland and lung with a history of Sjӧgren syndrome.20,22,23   In view of this 
finding, we screened salivary gland MALT lymphoma for t(X;14)(p11;q32) by interphase FISH, and 
identified the translocation in 2/58 (3%) cases (Figure S4).  Interestingly, GPR34 mutation and 
translocation were mutually exclusive, together seen in 11/58 (19%) cases of salivary gland MALT 
lymphoma (Figure 1, Figure S4).   
 
TBL1XR1 mutation was most frequent in MALT lymphoma of salivary gland (14/58=24%), occurring 
less frequently in MALT lymphomas of the stomach (3/36=8%), lung (1/13=8%), ocular adnexa 
(7/115=6%), skin (1/8 =13%) and in a single case from tonsil, but not in the thyroid (Figure 1).  A total 
of 30 mutations were found in 27 cases, with 3 cases affected by two mutations. The majority of 
these mutations (20 missense changes and 5 inframe deletions) were within the WD40 domains and 
frequently affected regions or residues of structural importance, which are likely critical for 
interaction with NCoR (Figure 3). The remaining 5 mutations included 3 substitution changes at exon 
11 splice site, 1 frameshift deletion and 1 nonsense change, most likely resulting in truncated 
proteins with potential increased binding to UbcH5.24  
 
TET2 mutation was found in the majority of MALT lymphomas of the thyroid (8/13=62%), and also 
recurrently seen in those of salivary gland (5/58=9%), ocular adnexa (5/115=4%), stomach (3/36=8%) 
and lung (1/13=8%) (Figure 1).    A total of 31 TET2 mutations were detected in 23 cases, with 8 cases 
showing multiple mutations (Figure 2).  Interestingly, 7/8 of the cases with multiple TET2 mutations 
were MALT lymphomas of the thyroid.  The vast majority of these mutations were deleterious 
changes including 11 frameshift indels, 4 nonsense, 1 splice site and 15 missense mutations.  Of 
11 
 
these, the majority of frameshift (8/11) and nonsense (3/4) mutations were found in MALT 
lymphomas of the thyroid. 
  
To our surprise, TNFRSF14 mutation was highly frequent in MALT lymphoma of thyroid (6/13=46%), 
albeit infrequent in those of other sites (Figure 1).   A total of 21 TNFRSF14 mutations were detected 
in 18 cases, and all mutations were deleterious changes comprising 6 nonsense, 2 frameshift indel, 1 
inframe deletion, 11 missense changes including 2 in the first codon thus abolishing the translation 
start site, and a single splice site mutation (Figure 2).  As TNFRSF14 mutation is common in 
paediatric-type follicular lymphoma and the mutations identified are of similar nature,25  we 
carefully reviewed the histopathology and immunophenotype of our cases with TNFRSF14 
mutations, where necessary performed further immunohistochemistry for CD10 and BCL6, and also 
FISH for BCL2 and BCL6 translocation.  These additional analyses confirmed the original diagnosis of 
MALT lymphoma in these cases.  
 
PIK3CD was another gene frequently mutated in MALT lymphoma of thyroid (3/13=23%), followed 
by salivary gland (5/58=9%), but rarely in those of other sites (Figure 1).   A total of 11 PIK3CD 
mutations were identified in 11 MALT lymphomas, and the vast majority of these mutations were 
missense changes including N334K and E1021K, previously reported in patients with activated PI3Kδ 
syndrome (hyper IgM syndrome) and in DLBCL (Figure 2).26-29   
 
Mutation in the remaining genes was relevantly infrequent, without any apparent bias among the 
sites examined.  Mutation in CCR6 was recurrent, and seen in a total of 7 MALT lymphomas, with 7 
mutations including 5 deleterious changes (3 nonsense, 3 frameshift indels) and 2 missense changes, 
largely clustered in the C-terminal regulatory region (Figures 1&2).   Interestingly, mutations in 
GPR34 and CCR6, both members of the GPCR family, were mutually exclusive. 
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Distinct association of genetic changes in MALT lymphoma of various sites 
 
Correlation analysis revealed several distinct associations among genetic changes in MALT 
lymphoma of different sites.  In salivary gland MALT lymphoma, there was a significant association 
between TBL1XR1 mutation and GPR34 mutation/translocation (P=0.0002), with TBL1XR1 mutation 
seen in 8/11 (73%) cases with GPR34 mutation/translocation, but only in 6/47 (13%) cases without 
GPR34 genetic abnormalities (Figure 4, Figure S5).  Both GPR34 and TBL1XR1 genetic changes were 
more frequently seen in the cases with non-IGHV1-69 than those with IGHV1-69 rearrangement 
(29% vs 9%; 57% vs 18% respectively) although this does not reach statistical significance. 
 
In ocular adnexal MALT lymphoma, TBL1XR1 mutation was mutually exclusive from TNFAIP3 
mutation (P=0.049), but significantly associated with PIK3CD mutation (P=0.009), with TBL1XR1 
mutation seen in 2/3 (67%) cases with PIK3CD mutation, but in only 5/112 (4%) cases without 
PIK3CD mutation (Figure4, Figure S5).   TBL1XR1 mutation was also mutually exclusive from IGHV4-
34 rearrangement, but significantly associated with IGHV3-23 usage (P=0.03), with TBL1XR1 
mutation seen in 3/11 (27%) cases with IGHV3-23 rearrangement, but in only 2 /52 (4%) cases with 
other rearrangements (Figure 4).  MYD88 mutation also appeared to be more frequent in TBL1XR1 
mutated cases  (2/7=29%) compared to non-mutated cases (6/108= 6%), although this did not reach 
significance  (P=0.07). 
 
In gastric MALT lymphoma, t(11;18) API2-MALT1 was mutually exclusive from other genetic changes 
(Figure S5, P=0.025). 
 
Correlation between genetic changes and clinicopathological parameters 
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This was carried out in 98 cases of ocular adnexal MALT lymphoma where clinicopathological data 
were available (Table S8).   TBL1XR1 mutation and IGHV3-23 usage were significantly associated with 
involvement of the conjunctiva (P=0.002 in each respectively), while TNFRSF14 mutation was 
significantly associated with involvement of the orbit (P=0.04).  MYD88 and TP53 mutations were 
much higher in cases involving both orbit and conjunctiva than those involving only a single site but 
only the former showing a statistical significance (4/23=17% vs 2/75=3%, P=0.03).    With the 
exception of TNFAIP3 deletion/mutation that was significantly associated with higher radiation 
dosages to achieve complete remission as reported previously,16, none of the other genetic changes 
showed any significant association with radiation dosages.   
 
DISCUSSION 
By whole exome sequencing of 21 cases of MALT lymphomas of the salivary gland and thyroid, we 
have identified several novel genetic changes in MALT lymphoma, including GPR34 and CCR6 
mutations not yet previously reported in human malignancies.  Screening these newly identified 
mutations revealed distinct mutation profiles in MALT lymphoma of various sites, and provide 
further evidence of potential oncogenic cooperation between receptor signalling and genetic 
changes.   
 
GPR34 and CCR6 mutations in MALT lymphoma  
 
Both GPR34 and CCR6 are members of class A G protein-coupled receptor (GPCR) superfamily, which 
transduce extracellular stimulation into intracellular signalling through G protein and β-arrestin.  By 
interacting with G protein, GPCR can activate diverse signalling pathways critical for cellular function.  
This receptor signalling is tightly regulated through a process known as desensitization that is 
mediated by GPCR phosphorylation, allowing its binding to β-arrestin which triggers receptor 
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internalisation, consequently dampening intracellular signalling.30  A common phosphorylation code 
(motif) has been identified in the C-terminal cytoplasmic tail of most GPCRs, and its phosphorylation 
enables electrostatic interactions with β-arrestin.31 
 
GPR34 contains 7 transmembrane domains, followed by a C-terminal cytoplasmic tail.  The majority 
of GPR34 mutations identified in MALT lymphoma are nonsense changes or frameshift indels that 
are clustered in its C-terminal region, resulting in truncated proteins.  A phosphorylation code 
(motif) (S351S353T356) is seen in the C-terminal cytoplasmic tail of GPR34 according to Zhou et al,31 and 
all the above nonsense and frameshift changes would eliminate or impair these phosphorylation 
sites, thus potentially deregulating the receptor desensitization process.    
 
The remaining GPR34 mutations are missense changes including R84H, D151A and Y327N.  R84H 
affects the tri-basic motif (RKR) in the first intracellular loop, which is the key topogenic signal 
determining the orientation of the first transmemberane domain.32  D151A affects the highly 
conserved E/DRY motif and is predicted to cause the receptor constitutive activation.33  Y327N is 
close to the interface of the seventh TM domain and the cytoplasmic tails, and is predicted to be 
highly damaging by PolyPhen-2, although its potential functional impact is unclear. 
 
Similarly, CCR6 also contains 7 transmemberane domains, followed by a C-terminal cytoplasmic tail, 
and the majority of CCR6 mutations are nonsense or frameshift changes that are clustered in its C-
terminal region.  A phosphorylation code (motif) (S357T360T363) is present in the C-terminal 
cytoplasmic tail of CCR6,31 and all the nonsense and frameshift changes identified would eliminate 
these phosphorylation sites, potentially impairing the receptor desensitization process.   The 
functional impact of the two CCR6 missense mutations (R159S and Y352C) is unclear. 
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The nature and distribution of mutations in GPR34 and CCR6 identified in this study are very similar 
to those seen in CXCR4 in Waldenström’s macroglobulinaemia and WHIM syndrome, as well as those 
found in CCR4 in adult T cell leukaemia/lymphoma, which have been shown to be gain-of-function 
changes.34-36  Despite their similar mutation pattern, GPR34 and CCR6 have distinct ligands, thus 
respond to different environmental cues, potentially explaining their differential involvement in 
MALT lymphoma of different sites.   GPR34 has been shown to be triggered by lyso-
phosphatidylserine, while CCR6 is activated by CCL20.37-39 Over-expression of wild type GPR34 in 
vitro resulted in ERK, PI3K/AKT and PKC signalling, inducing AP1 and NF-κB-mediated gene 
transcription.20,40  It remains to be investigated whether the above GPR34 and CCR6 mutations 
impact similar downstream signalling pathways, and if they would enhance these intracellular 
signalling pathways through impaired receptor desensitization and internalisation or via 
independent mechanisms.   
 
Distinct genetic profile in MALT lymphoma of various sites. 
 
The present study provides further evidence showing distinct genetic profiles among MALT 
lymphoma of various sites (Figure 1).  MALT lymphoma of the salivary gland features frequent 
mutation of TBL1XR1 and GPR34, while those of the thyroid are characterised by frequent mutations 
in TET2, TNFRSF14 and PIK3CD.  MALT lymphoma of the ocular adnexa is noted for frequent TNFAIP3 
mutation.  In contrast, MALT lymphomas of the stomach and lung are distinguished by a high 
prevalence of t(11;18)(q21;q21).   
 
The present study also unravels several distinct associations among genetic changes in MALT 
lymphoma.  In MALT lymphoma of the salivary gland, there is a significant positive association 
between TBL1XR1 mutation and GPR34 mutation/translocation.  The effect of TBL1XR1 mutations 
has not been fully characterised, but a previous report suggests that mutations enhance TBL1XR1 
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binding to NCoR and facilitate its degradation, consequently promoting NF-B and JUN target gene 
expression.41  Thus, TBL1XR1 mutation may sustain GPR34 mediated NF-kB and AP1 activation via 
this mechanism.  
 
Why GPR34 mutation and translocation are preferentially associated with MALT lymphoma of the 
salivary gland is unclear.   GPR34 has been shown to be activated by lyso-phosphatidylserine, which 
could be generated by hydrolysis of the exposed membrane lipids in apoptotic cells through 
phospholipase A.37,38  Among MALT lymphoma of various sites, the lymphoepithelial lesions are most 
prominent in those of salivary gland.   It remains to be investigated whether such lymphoepithelial 
lesions may facilitate the production of lyso-phosphatidylserine, the ligand for GPR34, thereby 
facilitating the expansion and localisation of B-cells carrying GPR34 genetic changes surrounding the 
lymphoepithelial lesion.   
 
In MALT lymphoma of the ocular adnexa, TBL1XR1 mutation is mutually exclusive from TNFAIP3 
mutation and IGHV4-34 usage, but significantly associated with IGHV3-23 usage and PIK3CD 
mutation, albeit with limited numbers of cases involved,   Like IGHV4-34 rearrangements, the IGHV3-
23 rearrangement seen in ocular adnexal MALT lymphoma also encodes autoreactive BCR as shown 
by recombinant antibody studies.5  In this context, the significant association between TBL1XR1 
mutation and IGHV3-23 rearrangement is very much analogous to that between TNFAIP3 mutation 
and IGHV4-34 rearrangement reported previously,17 hence expanding the evidence supporting 
oncogenic cooperation between antigenic drive and acquired genetic changes in MALT lymphoma.  
Similarly, the significant association between TBL1XR1 and PIK3CD mutation may also signify 
oncogenic cooperation between the two genetic events. 
 
In summary, our study reveals several novel genetic changes including GPR34 and CCR6 mutations 
not yet reported in human malignancies, and provides further evidence of distinct mutation profiles 
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in MALT lymphoma of various sites.  These novel findings offer exciting prospects for further 
characterisation of the molecular pathogenesis of MALT lymphoma.  
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FIGURE  LEGENDS:  
 
Figure 1:   Distinct mutation profiles in MALT lymphoma of various sites.   A total of 27 genes 
including the 10 MALT lymphoma associated genes indentified in the present study were screened 
for mutation by targeted sequencing, but only those showing recurrent changes are presented here.  
API2-MALT1 denotes t(11;18)(q21;q21) from previous studies,11,12  GPR34 results in MALT lymphoma 
of the salivary gland include both mutation and t(X;14)(p11;q32)/GPR34-IGH.   MALT lymphomas of 
salivary gland are featured by frequent TBL1XR1 and GPR34 mutations, while those of thyroid by 
frequent TET2, TNFRSF14 and PIK3CD mutations, and ocular adnexa by frequent TNFAIP3 mutation.   
 
Figure 2:  Nature and distribution of mutations in newly identified MALT lymphoma associated 
genes.   The site of MALT lymphoma in which mutation was identified is indicated by colour:  salivary 
gland in blue, thyroid in red, ocular adnexa in green, stomach in orange, lung in purple and other 
sites in grey.  TM: transmembrane domain,  ABD: adaptor binding domain, RBD: ras binding domain, 
DSBH: double-stranded β-helix. 
 
Figure 3. Nature and distribution of TBL1XR1 mutations in MALT lymphoma, and their potential 
functional impact.  
A) TBL1XR1 mutations identified in this study.  The site of MALT lymphoma in which mutation was 
identified is indicated by colour:  salivary gland in blue, thyroid in red, ocular adnexa in green, 
stomach in orange, lung in purple and other sites in grey.  
B) Detailed analyses of TBL1XR1 mutations within the WD40 domains.   TBL1XR1 mutations 
identified in the present and a previous study by Jung et al are included in the analyses.41  The 
majority of TBL1XR1 mutations are localised in the regions of structural importance, such as HSDW 
tetrad indicated by arrows and the residues predicted to be top facing (WDSP predictor, indicated in 
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red text).  The approximate position in the HMM logo for WD40 repeats (Prosite PS00678) is shown 
below the sequence.    
 
Figure 4.  Significant association among genetic changes in MALT lymphoma of the salivary gland and 
ocular adnexa.  In both cohorts, samples lacking the described changes are not included.  P value in 
red colour indicates a positive correlation, while P value in black colour denotes a negative 
correlation, with bold font indicating significant values. X indicates inactivating frameshift and 
nonsense mutations. d indicates deletion, s indicates splice site mutations and T indicates 
translocation. 
Figure 1. Distinct mutation profiles in MALT lymphoma of various sites.   A total of 27 genes including the 10 
MALT lymphoma associated genes indentified in the present study were screened for mutation by targeted 
sequencing, but only those showing recurrent changes are presented here.  API2-MALT1 denotes 
t(11;18)(q21;q21) from previous studies,11,12  GPR34 results in MALT lymphoma of the salivary gland include 
both mutation and t(X;14)(p11;q32)/GPR34-IGH.   MALT lymphomas of salivary gland are featured by 
frequent TBL1XR1 and GPR34 mutations, while those of thyroid by frequent TET2, TNFRSF14 and PIK3CD 
mutations, and ocular adnexa by frequent TNFAIP3 mutation.  
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Figure 4.  Significant association among genetic changes in MALT lymphoma of the salivary gland and 
ocular adnexa. In both cohorts, samples lacking the described changes are not included.   P value in red 
colour indicates a positive correlation, while P value in black colour denotes a negative correlation, 
with bold font indicating significant values. X indicates inactivating frameshift and nonsense mutations. 
d indicates deletion, s indicates splice site mutations and T indicates translocation. 
